

OPTIMA HEALTH PLAN

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **Incomplete form will delay authorization process.**

Drug Requested: **Xeljanz® (tofacitinib) / Xeljanz® XR® (tofacitinib xr) (Non-Preferred)**

DRUG INFORMATION: Complete information below or authorization will be delayed.

Drug Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

CLINICAL CRITERIA: **ALL** boxes **MUST** be checked to qualify to ensure authorization process will **NOT** be delayed..

• Prescriber is (check applicable box below)

Rheumatologist

Gastroenterologist

DIAGNOSIS: Applicable diagnosis below **MUST** be checked to qualify. All chart notes **MUST** be attached to this request to ensure authorization process will **NOT** be delayed.

Part A - DMARD therapy

Trial and failure of at least **one DMARD** therapy for at least **three (3) months (check each tried):**

<input type="checkbox"/> 6-mercaptopurine	<input type="checkbox"/> methotrexate	<input type="checkbox"/> azathioprine
<input type="checkbox"/> hydroxychloroquine	<input type="checkbox"/> auranofin	<input type="checkbox"/> sulfasalazine
<input type="checkbox"/> leflunomide	<input type="checkbox"/> aminosalicylates	<input type="checkbox"/> Other: _____
<input type="checkbox"/> olsalazine (Crohn's/Ulcerative Colitis)	<input type="checkbox"/> mesalamine (Crohn's/Ulcerative Colitis)	

Moderate-to-Severe Active Rheumatoid Arthritis

Prescriber is a Rheumatologist

AND

Patient is at least 18 years old and diagnosed with one of the following:

AND

Patient has tried and failed at least **one DMARD** for at least **three (3) months (REFER TO PART A DMARD Therapy)**

AND

Trial and failure of **two (2)** of the **PREFERRED** biologics below:

<input type="checkbox"/> Cimzia®	<input type="checkbox"/> Humira®	<input type="checkbox"/> Simponi®
----------------------------------	----------------------------------	-----------------------------------

Active Psoriatic Arthritis

Prescriber is a Rheumatologist

AND

- Patient has tried and failed at least **one DMARD** for at least **three (3) months** (**REFER TO PART A DMARD Therapy**)

AND

- Trial and failure of **two (2)** of the **PREFERRED** biologics below:

<input type="checkbox"/> Cimzia®	<input type="checkbox"/> Humira®	<input type="checkbox"/> Stelara®	<input type="checkbox"/> Simponi®
----------------------------------	----------------------------------	-----------------------------------	-----------------------------------

For Ulcerative Colitis indication:

- Prescriber is a Gastroenterologist

AND

- Patient is at least 18 years old

AND

- Disease is moderately to severely active with inadequate response to:
 - 90 day trial of aminosalicylate or DMARD (**Refer to Part A**), **AND**
 - budesonide or high dose steroids (40-60 mg prednisone daily)

AND

- Trial and failure of **two (2)** of the **PREFERRED** biologics below:

<input type="checkbox"/> Humira®	<input type="checkbox"/> Simponi®
----------------------------------	-----------------------------------

Forms can be found at www.optimahealth.com

Medication being provided by (check applicable box(es) below):

- Physician's office **OR** Specialty Pharmacy - PropriumRx:

****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.****

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.

Patient Name: _____

Member Optima #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

DEA OR NPI #: _____

*Approved by Pharmacy and Therapeutics Committee: 4/17/2013; 7/19/2018;
REVISED/UPDATED: 3/30/2016; 8/11/2016; 9/22/2016; 12/21/2016; 8/5/2017; 12/28/2017; 2/19/2018; 11/23/2018